These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6866215)

  • 1. Elevation of serum corticosterone in rats by dopamine agonists related in structure to pergolide.
    Fuller RW; Snoddy HD; Mason NR; Clemens JA; Bemis KG
    Neuroendocrinology; 1983; 36(4):285-90. PubMed ID: 6866215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists.
    Fuller RW; Snoddy HD
    Neuropharmacology; 1984 Dec; 23(12A):1389-94. PubMed ID: 6527743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated administration of pergolide to rats attenuates the acute elevation of serum corticosterone by pergolide.
    Fuller RW; Snoddy HD
    Pharmacol Biochem Behav; 1981 Dec; 15(6):933-6. PubMed ID: 7323119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of serum corticosterone concentrations in rats by pergolide and other dopamine agonists.
    Fuller RW; Snoddy HD
    Endocrinology; 1981 Oct; 109(4):1026-32. PubMed ID: 6116593
    [No Abstract]   [Full Text] [Related]  

  • 5. Altered behavioral response to a D2 agonist, LY141865, in spontaneously hypertensive rats exhibiting biochemical and endocrine responses similar to those in normotensive rats.
    Fuller RW; Hemrick-Luecke SK; Wong DT; Pearson D; Threlkeld PG; Hynes MD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):354-9. PubMed ID: 6138425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molindone: higher doses needed to block pergolide-induced elevation of serum corticosterone than to elevate dopamine metabolites in brain.
    Fuller RW; Snoddy HD
    Life Sci; 1983 Dec; 33(23):2357-61. PubMed ID: 6645804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonists.
    Fuller RW; Hemrick-Luecke SK; Perry KW; Toomey RE
    J Pharm Pharmacol; 1985 Apr; 37(4):268-70. PubMed ID: 2860228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a stereospecific D2-dopamine agonist on acetylcholine concentration in corpus striatum of rat brain.
    Wong DT; Bymaster FP; Reid LR; Fuller RW; Perry KW; Kornfeld EC
    J Neural Transm; 1983; 58(1-2):55-67. PubMed ID: 6655467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further characterization of tolerance to the corticosterone-elevating effect of pergolide in rats.
    Gust CM; Fuller RW
    Neurosci Lett; 1988 Nov; 93(2-3):307-11. PubMed ID: 2907374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of specific D-1 and D-2 dopamine agonists (LY141865 and SKF-38393) and pergolide on urinary output of rats.
    Leander JD
    Arch Int Pharmacodyn Ther; 1987 Oct; 289(2):290-5. PubMed ID: 2962555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats.
    Cavero I; Lefevre-Borg F; Lhoste F; Sabatier C; Richer C; Giudicelli JF
    J Pharmacol Exp Ther; 1984 Mar; 228(3):779-91. PubMed ID: 6707926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of epinephrine in rat hypothalamus by a dopamine agonist, pergolide.
    Fuller RW; Perry KW; Hemrick-Luecke SK
    Neurochem Res; 1982 Apr; 7(4):399-405. PubMed ID: 6125905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flumezapine, an antagonist of central dopamine and serotonin receptors.
    Fuller RW; Mason NR
    Res Commun Chem Pathol Pharmacol; 1986 Oct; 54(1):23-34. PubMed ID: 2879325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain.
    Jiang DH; Reches A; Wagner HR; Fahn S
    Neuropharmacology; 1984 Mar; 23(3):295-301. PubMed ID: 6539428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist.
    Foreman MM; Fuller RW; Hynes MD; Gidda JS; Nichols CL; Schaus JM; Kornfeld EC; Clemens JA
    J Pharmacol Exp Ther; 1989 Jul; 250(1):227-35. PubMed ID: 2526214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y; Fage D; Zivkovic B; Scatton B
    J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in hypothalamic epinephrine concentration and other neurochemical changes produced by quinpirole, a dopamine agonist, in rats.
    Fuller RW; Hemrick-Luecke SK
    J Neural Transm; 1985; 61(3-4):161-73. PubMed ID: 3157777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist.
    Gust CM; Hemrick-Luecke SK; Fuller RW
    J Neural Transm; 1989; 75(1):11-20. PubMed ID: 2563751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptors, controlling dopamine levels in rat adrenal glands-comparison with central dopaminergic autoreceptors.
    Kujacic M; Svensson K; Löfberg L; Carlsson A
    J Neural Transm Gen Sect; 1991; 84(3):195-209. PubMed ID: 1679336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.